Search results

Technologies 34

View all

• Instrument-Free Molecular Diagnostics
  A synthetic biology-based molecular diagnostics platform that enables the creation of low-cost, highly accurate tests for non-clinical settings.
• AminoX: Making Better Protein Drugs, Quicker and Cheaper
  AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition.
• Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
  eLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance.
• Ichor: Reversing Aging
  Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health.
• Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
  This nanotech-based diagnostic platform uses a unique nucleation mechanism that assembles a DNA "nanoseed" in the presence of a pathogen-derived biomarker that then is amplified within 15 minutes to create a signal for easy detection. It is highly robust, and cost-effective, and can be adapted to detect a variety of biomarkers.
• Paper-Based Diagnostics
  With the imminent threat of new pandemics and frequent disease outbreaks exemplified by the recent Ebola and Zika epidemics, there is a growing need for low-cost, easily deployable and simple-to-use diagnostic tools. The Wyss Institute has developed paper-based synthetic gene networks as a next generation diagnostic technology for use in global healthcare crises and patient...

Collaborations 1

• Brigham-Wyss DxA
  The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests.

News 247

View all

• Press Release
  
  A better way to make RNA drugs
  July 12, 2024
• Press Release
  
  A model of Collaborative Ethics to guide translational research from fundamental discoveries to real-world applications
  June 25, 2024
• Community
  
  Reimagining treatment for neurological diseases: Ayush Noori
  June 11, 2024

Multimedia 68

View all

• 

  Video/Animation
  AminoX: Making Better Protein Drugs, Quicker and Cheaper
  A synthetic biology and advanced chemistry platform that efficiently incorporates non-standard amino acids by hacking the ubiquitous protein synthesis process. Credit: Wyss Institute at Harvard University

• 

  Video/Animation
  Atlantic Health Research Spotlight: Finding Balance in Bipolar Disorder Through Drug Prediction and Organoid-Based Drug Screening
  Innovation has disrupted care as we know it. Challenges with access, complex diseases, and care delivery persist, but so do areas of opportunity for emerging tech and discoveries. The Atlantic explored gene editing, artificial intelligence, climate change, weight-loss and diabetes treatments, and more at their Annual Health Summit. The Wyss’ Director of Synthetic Biology, Jenny...

• 

  Video/Animation
  Reimagine the World – Volume 3 – Northpond Edition
  The Wyss Institute’s alliance with Northpond Labs supports early-stage, transformative research with strong translation potential. Hear Northpond Ventures co-founders Michael Rubin and Sharon Kedar explain why they decided to partner with the Wyss, as well as the leaders of various Wyss projects and startups about how support from Northpond has helped accelerate their technologies to...

• 

  Video/Animation
  HarborSite Animation
  This animation explains how the Wyss Institute’s HarborSite genome editing technology uses highly specific and efficient recombinase enzymes and genomic safe harbors to achieve more predictable, safe, and durable gene therapies. Credit: Wyss Institute at Harvard University

• 

  Video/Animation
  Enhancing Lactation to Improve Infant and Maternal Health
  Lactation Biologics is developing a long-lasting, self-injectable treatment to help nursing mothers feed their babies naturally, helping them get the best nutrition possible in the face of climate disasters and supply chain disruptions. Credit: Wyss Institute at Harvard University

• 

  Audio/Podcast
  Ideas to Innovation – From Lab to Life: The Transformative Power of Synthetic Biology
  Rapid advancements in technology and science are shaping a new era, with artificial intelligence and synthetic biology, or “syn-bio,” at the forefront. Heralded as the next big leap in science, syn-bio involves redesigning organisms for useful purposes by engineering them to have new abilities. The importance of syn-bio for people and our planet cannot be...